Evidence map›Paper›PMID 30567734›Full record

ArticleThe Journal of biological chemistry2019

Tropomyosin pseudo-phosphorylation results in dilated cardiomyopathy.

Sudarsan Rajan, Ganapathy Jagatheesan, Natalia Petrashevskaya, Brandon J Biesiadecki, Chad M Warren, Tara Riddle, Stephen Liggett, Beata M Wolska, R John Solaro, David F Wieczorek

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. ALPK2 prevents cardiac diastolic dysfunction in heart failure with preserved ejection fraction.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sudarsan RajanFrom the Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267.
Ganapathy JagatheesanFrom the Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267.
Natalia Petrashevskayathe Department of Medicine, University of Maryland, Baltimore, Maryland 21201.
Brandon J Biesiadeckithe Department of Physiology and Biophysics, University of Illinois, Chicago College of Medicine, Chicago, Illinois 60612.
Chad M Warrenthe Department of Physiology and Biophysics, University of Illinois, Chicago College of Medicine, Chicago, Illinois 60612.
Tara RiddleFrom the Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267.
Stephen Liggettthe Department of Medicine, University of Maryland, Baltimore, Maryland 21201.
Beata M Wolskathe Department of Physiology and Biophysics, University of Illinois, Chicago College of Medicine, Chicago, Illinois 60612.
R John Solarothe Department of Physiology and Biophysics, University of Illinois, Chicago College of Medicine, Chicago, Illinois 60612.
David F WieczorekFrom the Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, david.wieczorek@uc.edu.ORCID 0000-0001-9819-8040
Illinois College · USUniversity of Cincinnati · USUniversity of Maryland, Baltimore · US

Funding

Sarcomeric Modifications and Progressive Cardiac MaladaptationP01HL062426 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DE TOMBE, PIETER P. · 2000 to 2020
$42.4M
Integrated Crosstalk of Thin Filament Post-translational ModificationsR01HL114940 · NHLBI · OHIO STATE UNIVERSITY · PI BIESIADECKI, BRANDON J · 2013 to 2021
$3.6M
Myofilament signaling and cardiac disordersR01HL128468 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SOLARO, R JOHN, WOLSKA, BEATA M. · 2016 to 2019
$1.6M
The Regulation of Sarcomeric Function by TropomyosinR01HL081680 · NHLBI · UNIVERSITY OF CINCINNATI · PI WIECZOREK, DAVID F · 2007 to 2010
$1.6M
NHLBI NIH HHS P01 HL062426NHLBI NIH HHS R01 HL081680NHLBI NIH HHS R01 HL114940NHLBI NIH HHS R01 HL128468
6 · The paper itself

Abstract

Phosphorylation of cardiac sarcomeric proteins plays a major role in the regulation of the physiological performance of the heart. Phosphorylation of thin filament proteins, such as troponin I and T, dramatically affects calcium sensitivity of the myofiber and systolic and diastolic functions. Phosphorylation of the regulatory protein tropomyosin (Tpm) results in altered biochemical properties of contraction; however, little is known about the physiological effect of Tpm phosphorylation on cardiac function. To address the

Indexed as

Actin CytoskeletonAnimalsCalciumCardiomyopathy, DilatedCells, CulturedMiceMice, TransgenicMutationMyofibrilsPhosphorylationTropomyosinCalciumTpm1 protein, mouseTropomyosincardiac musclecardiomyopathycasein kinasemuscle physiologymyofilamentphosphomimeticphosphorylationtransgenic micetropomyosin

Identifiers

PMID30567734
PMCPMC6393621
OpenAlexW2904725428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.